Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

What Was Tested

The paper reports a study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone), published as a randomized controlled trial.

The objective of the 26-week extension phase was to evaluate long-term safety and effects of tesamorelin.

Who Took Part

According to the abstract, 26, patients were involved.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, placebo-controlled and crossover.

Because people in this Tesamorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some patients received a placebo instead of Tesamorelin, giving a reference point.

In the crossover set-up each of the patients took both Tesamorelin and the comparison in turn, acting as their own control.

Safety included adverse events and glucose parameters.

What Was Measured

PubMed files the paper under topics including Adiponectin, Anti-Retroviral Agents, Biomarkers, Body Composition, C-Reactive Protein, Cholesterol and Growth Hormone-Releasing Hormone.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone) in 26, patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (AIDS (London, England)), a journal based in England.

More context: the Tesamorelin compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.